Introduction
Dissemination of Enterobacteriaceae that have acquired carbapenemase genes is a growing public health problem worldwide [1] . The prevalence of particular types of carbapenemases differs significantly between countries: Klebsiella pneumoniae carbapenemase (KPC) variants are prevalent in the United States, Greece, and Israel; Verona integron-encoded metallo-beta-lactamases (VIM) are frequently found in Greece and Italy; oxacillinase (OXA)-48 was first recovered and becoming prevalent in Turkey, while imipenemase (IMP)-type enzymes were mostly reported in the Far East [2] . Recently, isolates with New Delhi metallo-beta-lactamases (NDM-1) have been identified, mostly in patients who had a history of travel to the Indian subcontinent [3] .
In Belgium, sporadic cases of carbapenemase-producing Enterobacteriaceae (CPE) isolates have been reported, the majority of which occurred in patients returning from travel abroad [4] [5] [6] .
This longitudinal survey aimed to summarise the microbiological characteristics and clinical data of carbapenem-non-susceptible Enterobacteriaceae (CNSE) isolates, with a special focus on CPE isolates referred to the National Reference Centre (NRC) for multidrugresistant Enterobacteriaceae.
Methods
Enterobacteriaceae isolates were referred by local Belgian laboratories on a voluntary basis to the NRC (Centre Hospitalier Universitaire Mont-Godinne, Yvoir, Belgium). They were invited to send isolates that, according to antimicrobial susceptibility guidelines used in the respective laboratories, were resistant to third or fourth generation cephalosporins or carbapenem nonsusceptible, for detection or confirmation of enzymes conferring antibiotic resistance. In September 2008, following the detection of the first VIM-1-producing Klebsiella pneumoniae isolates causing nosocomial outbreaks in two Belgian hospitals [7] , a national alert was issued and local laboratories were asked to send carbapenem-non-susceptible isolates to the NRC for the detection or confirmation of carbapenemase production. All isolates referred between Janurary 2007 and April 2011 were re-tested at the NRC for antimicrobial susceptibility by the disk diffusion method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) and meropenem inhibition zones were recorded. Isolates displaying an inhibition zone of <23 mm to 10 µg meropenem disks, categorised retrospectively as intermediately resistant according to the CLSI interpretative criteria of January 2011 [8] , were screened for the presence of carbapenemase-encoding genes by PCR using primers specific for bla VIM, bla IMP, bla KPC, bla NDM and bla OXA-48 [6] . Carbapenemase-encoding genes were identified by sequencing of the amplicons. Clinical and demographic data, including recent travel and/or hospitalisation abroad, were collected for all patients carrying CPE strains. The evolution over time and the microbiological characteristics of the 44 CPE isolates detected during the study period are shown in Figures 2, 3 and 4. VIM-1 (n=18) and OXA-48 (n=16) were the most frequent carbapenemase enzymes found among CPE isolates.
Of the 44 different CPE isolates recovered from 39 different patients at 16 Belgian hospitals during the study period, 20 were isolated from urine, nine from rectal screening swabs (for the detection of asymptomatic carriers), seven from wound/drainage fluids, six from lower respiratory tract samples and three from blood culture specimens.
Of the 39 patients colonised or infected with a CPE isolate, only 16 had travelled abroad (13 of them in Mediterranean countries of Europe or North Africa) in the six months before the diagnosis (Table) . Eleven of the 23 autochthonous CPE cases, probably resulting from local secondary acquisition, carried VIM-1-positive isolates (seven Klebsiella pneumoniae, two Serratia marcescens and two K. oxytoca) and were identified in eight hospitals. The 12 remaining patients harboured OXA-48-producing isolates (seven Enterobacter cloacae, four K. pneumonia and 1 Escherichia coli) and were detected in four hospitals. Four patients harboured more than one CPE isolates. Two patients were colonised by two NDM-1-positive isolates of two different species: one of them carried K. pneumoniae associated with E. coli and the other patient Morganella morganii with E. cloacae. One patient was colonised by two OXA-48-producing isolates (one E. cloacae Number of isolates
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Morganella morganii Providencia rettgeri Citrobacter braakii Klebsiella oxytoca
Serratia marcescens Escherichia coli Enterobacter cloacae Klebsiella pneumoniae
and one E. coli). In one patient one VIM-1-producing Providencia rettgeri, one VIM-1-positive Citrobacter freundii and one KPC-2-producing K. pneumoniae were detected simultaneously. Retrospective review of clinical data charts showed that 25 patients were considered colonised by CPE isolates while 14 patients were considered to be infected. The infections were urinary tract infections (n=7), lower respiratory tract infections (n=2), soft-tissue and skin infections (n=2) and blood stream infections (n=3).
Discussion
Our data clearly demonstrate a significant increase of CNSE isolates referred to the NRC and of CPE isolates detected in Belgian hospitals particularly since 2010. [9] .
In Belgium, no resistance survey of Enterobacteriaceae isolates with decreased susceptibility to carbapenems has been conducted to date and thus no data are available regarding the true prevalence of CNSE isolates. It is possible that a certain number of CNSE and CPE isolates were missed, especially those producing OXA-48 and lacking expanded-spectrum cephalosporin-hydrolysing beta-lactamase [10] .
It is presently unclear whether the apparent increase in the isolation of CNSE and CPE is due to the spreading potential of these microorganisms or rather reflects the application of more effective detection methods by clinical laboratories. The decreasing number of total isolates referred to NRC from 2007 to 2010 cannot be explained, but together with the significantly increasing number of CNSE isolates referred, could result in the relative increase of CNSE or CPE. Since that the isolates were referred on a voluntary basis, a better knowledge or application of detection methods for ESBL-carrying or AmpC cephalosporinase-producing strains by local laboratories could result in a decreased need for confirmation and referral of these isolates to the NRC. It is possible as well that the adherence to the EUCAST breakpoints or to the revised CLSI interpretative criteria for carbapenems published in June 2010 [11] could have improved the detection of CNSE and of CPE isolates by clinical laboratories. The increased sensitivity of detection, together with a better awareness of clinical microbiologists, might in part explain the higher number of CNSE isolates referred to the NRC since 2010. Nevertheless, the diversification of both the species and the carbapenemase-encoding genes detected in CPE isolates is a matter of concern. Moreover, the significant proportion of non-travel associated CPEpositive patients suggests the local establishment and spread of carbapenemase-producing enterobacteria in Belgium. These data clearly underline the importance of a systematic and coordinated national surveillance programme for rapid detection and reporting of CPE isolates in order to prevent their further dissemination. Finally, our experiences suggest that at a European level, the implementation of harmonised and accurate detection methods should be encouraged and that specific guidelines of management including infection control measures are urgently needed in order to limit the spread of these multidrug-resistant organisms.
